Elsevier

Vaccine

Volume 24, Issue 6, 6 February 2006, Pages 703-707
Vaccine

Short communication
Vaccination of yeast sensitive individuals: review of safety data in the US vaccine adverse event reporting system (VAERS)

https://doi.org/10.1016/j.vaccine.2005.07.069Get rights and content

Abstract

The preparation of recombinant hepatitis B vaccines involves using cellular cultures of Saccharomyces cerevisiae, otherwise known as baker's yeast. Prior to vaccine licensure, clinical trials were performed to address whether residual yeast proteins in the vaccines could induce anaphylaxis, including testing for IgE anti-yeast antibody levels. 1–2% of subjects had anti-yeast IgE antibodies before immunization, but demonstrated no significant rise in IgE after HBV. We searched reports in the Vaccine Adverse Event Reporting System (VAERS) for those that mentioned a history of allergy to yeast and then reviewed the adverse events described in these reports for potential anaphylactic reactions. Probable anaphylaxis was defined as the presence of one or more dermatologic symptoms and one or more respiratory, gastrointestinal, or cardiovascular symptoms with onset within 4 h of Hepatitis B vaccination. Possible anaphylaxis was defined in one of two ways: (1) cases that described dermatologic or respiratory symptoms (but not both) occurring within 4 h of vaccination; or (2) cases that described one or more dermatologic and/or respiratory symptoms occurring 4–12 h post vaccination. Among the 107 reports of pre-existing “yeast allergies,” 11 reports described probable or possible anaphylaxis after HBV. Four additional cases were described after other vaccines. The majority of vaccinees who met the case definitions and had a history of yeast allergies were female, ages ranged from 10 to 64, and symptom onset ranged from 15 min to 5 h after vaccination. No deaths were reported. The small number of reports to VAERS may be partly due to health care professionals observing current contraindications by not vaccinating yeast sensitive individuals. Nevertheless, yeast associated anaphylaxis after HBV in sensitized patients appears to be a rare event.

Introduction

In the United States, two kinds of hepatitis B vaccines (HBV) have been produced and distributed. Plasma-derived HBV are no longer manufactured in the United States; all current HBV are produced by recombinant methods [1]. Modern genetically engineered HBV are highly effective and safe products [2]. They are prepared by harvesting hepatitis B surface antigen from cell cultures of recombinant strains of Saccharomyces cerevisiae (common bakers’ yeast) that carry the surface antigen gene of hepatitis B virus. As a result of biochemical and biophysical purification, there is no detectible yeast DNA and only trace amounts of yeast proteins (1–5%) in the final vaccine products [3], [4], [5], [6], [7]. Two polysaccharide vaccines, HibTITER and Prevnar, include a conjugating protein (CRM197) isolated from cultures of Corynebacterium diphtheriae grown in a yeast extract-based medium. However, the final vaccine products do not contain yeast protein [8], [9]. Whether these residual yeast proteins in HBV could act as antigens or allergens in vaccinees was evaluated early in vaccine development. To address this issue, testing for both IgG and IgE antibodies against yeast proteins were performed in small subsets (50–133 subjects) of volunteers participating in clinical trials [10], [11], [12]. Hundred percent of subjects had IgG antibodies against yeast even before vaccination, presumably due to prior exposure by, for example, eating bread. The titers of these IgG antibodies rose, fell, or remained unchanged after immunization, but showed no consistent pattern and were not related to any clinical complaints after vaccination. 1–2% of subjects had anti-yeast antibodies of the IgE class even prior to immunization, but received the vaccine uneventfully and had no significant rise in the titer of these antibodies. It was concluded from these studies that the small amounts of yeast proteins in recombinant HBV do not provoke immune reactions in vaccine recipients or cause allergic reactions in the rare subjects with pre-existing anti-yeast IgE antibodies. Further, IgE-mediated allergy to yeast as an aeroallergen or food allergen is actually quite rare, although it may have some immunologic cross-reactivity with other fungi [13], [14], [15]. In a study of 193 bakery workers, including 104 filing claims for baker's asthma, none had positive skin tests to baker's yeast [15]. A potentially confounding circumstance is the belief by some patients and practitioners in the “yeast hypersensitivity syndrome” [16]. In this “syndrome,” a wide range of ill-defined symptoms is attributed to exposure to the yeast, Candida albicans. This organism is actually part of normal human flora, and the condition lacks biologic plausibility and has been deemed unproven. Patients who believe they suffer from this malady may think of themselves as “allergic to yeast”, but even the proponents of this entity do not claim it is IgE mediated or causes anaphylaxis. Nonetheless, hypersensitivity to yeast is listed in HBV package inserts as a contraindication for HBV administration [4], [5], [6], [7], [8].

In the US, a nationwide post-marketing monitoring system for vaccine safety known as the vaccine adverse event reporting system (VAERS) has been in place since 1990. The goal of this review was to find if adverse events (AE) have been reported to VAERS following vaccination of individuals reportedly allergic to yeast. We were particularly interested in identifying and describing possible IgE-mediated anaphylactic reactions.

Section snippets

Methods

VAERS is a spontaneous reporting system for adverse events following vaccination with US licensed vaccines that is maintained by the U.S. Department of Health and Human Services [17], [18]. VAERS accepts AE reports from vaccine providers, other healthcare workers, vaccinees or their parents, and other reporters, either directly or via vaccine manufacturers. The VAERS form provides space for comments regarding the vaccinee's pre-existing physician-diagnosed allergies and other medical conditions

Results

From July 1, 1990 through July 1, 2004, there were 180,895 adverse event reports submitted to VAERS. Additionally, the Centers for Disease Control and Prevention biologics surveillance data from 1991–2001 indicate a distribution of more than 276 million doses of HBV in the United States [18]. Among VAERS reports, we identified 107 reports that mentioned a history of allergy to yeast that was present prior to vaccination and occurrence of adverse symptoms. Eighty-two of these 107 reports

Discussion

Reviews of post-marketing experience with recombinant HBV have confirmed a favorable safety profile for these vaccines [21], [22], [23]. Cases and case-series of various severe adverse reactions occurring in temporal association with HBV have been described in the literature. Some of them, e.g. neurological and autoimmune conditions, have caused controversy; however, the consensus today is that even if some of these reactions are causally related to HBV, the rate of these reactions is very

References (32)

  • M. Russell et al.

    Vaccination of persons allergic to latex: a review of safety data in the Vaccine Adverse Event Reporting System (VAERS)

    Vaccine

    (2004)
  • J.M. Kelso

    The gelatin story

    J Allergy Clin Immunol

    (1999)
  • Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal...
  • P. Duclos

    Safety of immunisation and adverse events following vaccination against hepatitis B

    Exp Opin Drug Saf

    (2003)
  • COMVAX (Merck). Haemophilus b conjugate (meningococcal protein conjugate) and hepatitis B (recombinant) vaccine. Merck...
  • ENGERIX-B (GlaxoSmithKline) Hepatitis B vaccine (recombinant). GlaxoSmithKline; 2004. Vaccine package...
  • Cited by (0)

    1

    Co-corresponding author.

    2

    Present address: Meningitis and Special Pathogens Branch, NCID/CDC, Mail Stop C09, Atlanta, GA 30333, USA.

    View full text